Trial Profile
Assessment of safety and feasibility of regadenoson as a pharmacologic stressor for perfusion cardiac MR in a pilot cohort of pediatric and young-adult patients who have undergone arterial switch operation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary disorders
- Focus Adverse reactions
- 07 Dec 2018 New trial record